Modern PET-CT imaging in oncology.

What PET-CT actually is

A PET-CT scanner is two imaging modalities in a single gantry^[4]:

• PET (Positron Emission Tomography) detects pairs of 511 keV annihilation photons emitted simultaneously in opposite directions when a positron from a radiopharmaceutical injected into the patient annihilates with an electron in tissue. The coincidence detection of these photon pairs allows the scanner to reconstruct a 3-D map of where the radiopharmaceutical has accumulated in the body — a functional image.
• CT (Computed Tomography) provides a low-dose anatomical image during the same session, used both for attenuation correction of the PET data and for anatomical correlation of the PET findings.

The hybrid image — PET function fused onto CT anatomy — is the clinical product that has been the workhorse of modern cancer imaging since the early 2000s. PET-CT supplanted PET-alone scanners (no CT) within a few years of its introduction because the anatomical context the CT provides substantially improves clinical interpretation. PET-CT is used in nearly every clinical question in oncology imaging — staging, response assessment, restaging, detection of recurrence, detection of unknown primary.

Scanner evolution — analog photomultiplier tubes to silicon photomultiplier digital detectors

The fundamental change in PET-CT technology over the past 10-15 years is at the level of the photon detector. PET scanners detect the 511 keV photons from positron annihilation using scintillator crystals (typically LSO, LYSO, or BGO) coupled to photodetectors that convert light flashes to electrical signals^[5]:

Digital PET-CT scanners now in widespread clinical use include the Siemens Biograph Vision and Vision Quadra, GE Discovery MI and Omni Legend, Philips Vereos and Vereos Digital, and United Imaging uMI Vista — each based on SiPM detector technology with broadly similar clinical capability. The Biograph Vision class specifically is widely cited in published comparisons of digital vs analog systems^[6]. The vendor-specific differences are real but secondary to the underlying analog-to-digital shift, which is the central technical advance.

What better resolution and sensitivity actually mean clinically

The technical specifications translate to specific clinical advantages^[7]:

• Smaller lesion detection. Digital PET-CT systems can typically resolve and reliably characterise lesions in the 4-6 mm range, where analog systems struggled below 8-10 mm. For prostate cancer PSMA PET, neuroendocrine tumour DOTATATE PET, and small nodal metastases on FDG PET, this matters: small but clinically meaningful disease that would have been below detection threshold on older scanners is now visible.
• Shorter scan time. The typical FDG PET-CT scan on a digital scanner is 5-10 minutes versus 15-20 minutes on legacy systems. For patients with claustrophobia, severe back pain, or limited tolerance for lying flat, this is a meaningful improvement in the patient experience.
• Lower injected radiopharmaceutical dose. The higher sensitivity allows comparable image quality at substantially lower activity — typical FDG doses on digital scanners are 30-50% lower than on analog scanners for equivalent diagnostic image quality. For paediatric oncology and for patients undergoing repeated PET scans for response assessment, the cumulative dose reduction is clinically meaningful.
• More accurate SUV quantification. Standardised uptake values (SUVmax, SUVmean, SUVpeak) are central to quantitative response assessment — particularly using criteria like PERCIST for solid tumours and Deauville score for lymphoma. Digital scanners produce more reproducible quantification, supporting better cross-time comparison of pre-treatment and post-treatment scans within the same patient.
• Better SUV reproducibility across centres. Through the EARL (European Association of Nuclear Medicine Research Limited) accreditation programme, which standardises SUV measurements across participating scanners, modern digital systems support quantitative comparison across institutions.

AI image reconstruction — the second layer of advance

Beyond the detector hardware change, modern PET-CT clinical practice now routinely uses iterative reconstruction algorithms that go substantially beyond the filtered-back-projection methods of the early PET era^[8]:

• Iterative reconstruction (OSEM with point-spread-function modelling and time-of-flight) — established for over a decade, this is the baseline modern reconstruction approach. It produces higher-resolution images with better noise characteristics than simple filtered back-projection.
• Bayesian penalised-likelihood reconstruction (BPL) — including the vendor-specific Q.Clear (GE) and TrueX with HD-PET (Siemens). BPL reconstruction further improves quantification accuracy for small lesions and supports lower-dose imaging without quality loss.
• Deep-learning denoising — neural-network-based denoising layers (multiple vendor implementations including AIRTM, Subtle Medical, vendor-integrated tools) are increasingly used to further reduce image noise, particularly enabling shorter scan times or lower injected doses while maintaining diagnostic image quality. These are not yet uniformly standardised across vendors but are advancing rapidly.

The clinical translation of these reconstruction advances is similar to the detector hardware story: better lesion detection, lower dose, shorter scan time, and more reliable quantification. The two advances stack — modern best-practice imaging combines SiPM digital hardware with iterative/BPL/AI reconstruction.

What this means for FDG PET-CT — the workhorse oncology scan

F-18 fluorodeoxyglucose (FDG) is the most widely used PET radiopharmaceutical in oncology, and the clinical benefit of digital PET-CT for FDG imaging has been documented across multiple cancer types^[9]:

• Lymphoma — digital PET-CT improves Deauville score reproducibility for response assessment in Hodgkin and non-Hodgkin lymphoma; small residual disease detection is improved.
• Lung cancer — small pulmonary nodules and small mediastinal nodal metastases are more reliably characterised; integration with low-dose lung-cancer screening CT pathways improves.
• Head and neck cancer — small primary lesions in tongue base and tonsillar fossa, and small nodal metastases at level II, are better characterised; post-treatment recurrence at the primary site is more reliably distinguished from post-treatment inflammation.
• Oesophageal and gastric cancer — small nodal metastases and peritoneal disease are more reliably detected.
• Melanoma — small subcutaneous and visceral metastases are more reliably detected; response assessment after immune-checkpoint therapy benefits from the improved quantitative reproducibility.

FDG is not specific to cancer — it also accumulates in inflammation, infection, and active muscle — so the technical improvement does not change interpretation challenges. But the underlying image quality on which interpretation is based is substantially better than 10 years ago^[10].

What this means for PSMA PET-CT and DOTATATE PET-CT

The receptor-targeted PET radiopharmaceuticals — Ga-68 PSMA-11, F-18 PSMA-1007, Ga-68 DOTATATE, F-18 DOTATATE, and others — benefit particularly from the higher sensitivity and resolution of modern digital scanners^[11]:

• Ga-68 PSMA for prostate cancer — the proPSMA, OSPREY, and CONDOR trials established PSMA PET as superior to conventional imaging (CT, bone scan) for staging high-risk localised prostate cancer and for evaluating biochemical recurrence. Digital scanners support detection of small PSMA-positive nodes (in some cases under 5 mm) and small skeletal metastases that would have been below resolution on legacy systems. This is particularly relevant for biochemical recurrence with PSA in the 0.2-1.0 ng/mL range, where lesion-detection sensitivity is the limiting factor.
• Ga-68 DOTATATE for neuroendocrine tumours — for staging of low-volume neuroendocrine disease, identifying small somatostatin-receptor-positive lesions previously missed on conventional imaging, and supporting eligibility decisions for Lu-177 DOTATATE PRRT. Modern digital scanners improve the reliability of low-burden disease characterisation.

These improvements directly affect treatment decisions: a PSMA-positive node detected by digital PET that was missed by conventional imaging changes staging, changes radiotherapy planning, and changes systemic therapy decisions. For more on PSMA expression and PSMA PET specifically see our companion PSMA expression article.

Patient experience — what to expect during a modern PET-CT

For the cancer patient referred for a PET-CT today, the typical workflow is^[12]:

• Pre-scan preparation: For FDG PET-CT, fasting for 4-6 hours and avoidance of strenuous exercise for 24 hours before the scan. Blood glucose check on arrival (typically targeted under 200 mg/dL; specific cutoffs vary). Quiet rest in a warm room after injection.
• Injection: intravenous administration of the PET radiopharmaceutical — FDG, Ga-68 PSMA, Ga-68 DOTATATE, or another tracer depending on the clinical question. Activities are typically in the range 100-400 MBq depending on tracer, patient size, and scanner.
• Uptake period: typically 45-60 minutes of quiet rest while the radiopharmaceutical distributes through the body and accumulates at its biological targets. The patient is asked to remain still and to avoid talking or chewing (for FDG specifically).
• The scan itself: on a modern digital scanner, typically 5-10 minutes for whole-body acquisition (5-7 minutes on the newest LAFOV systems). The patient lies still on the scanner couch while the gantry slowly moves the body through the detector ring.
• Discharge: typically within 30-60 minutes after scan completion. Most patients can drive themselves; specific discharge instructions cover hydration, distance from young children for the rest of the day (for Ga-68 and F-18 tracers), and the return-to-work timeline.

The total in-clinic time from arrival to discharge is typically 90-120 minutes for an FDG PET-CT and 90-150 minutes for a Ga-68 PSMA or DOTATATE PET-CT. The scan-table time itself is the smaller part of the visit.

Radiation dose considerations

The radiation dose from a PET-CT scan comes from two sources: the injected PET radiopharmaceutical, and the low-dose CT that accompanies it^[13]:

For context: natural background radiation in most parts of the world is approximately 2-3 mSv per year. A typical diagnostic abdominal CT delivers approximately 8-10 mSv. PET-CT therefore sits in the range of standard cancer-imaging radiation exposure and is justified by the diagnostic information gained. Practice operates under ICRP and national regulator (AERB in India) authorisation, with formal dose-reference-level monitoring at accredited centres^[14].

Limitations and quality considerations

Modern PET-CT is a major clinical advance, but it has real limits that the referring oncologist and patient should understand^[15]:

• FDG is not cancer-specific. It also accumulates in inflammation, infection, brown fat, healing tissue, and active muscle. False-positive findings are well-recognised and require expert reading of the functional image alongside the anatomical CT, clinical context, and prior imaging.
• Not all cancers are FDG-avid. Well-differentiated neuroendocrine tumours, low-grade prostate cancer, well-differentiated renal cell carcinoma, and some lymphoma subtypes show low FDG uptake — alternative tracers (Ga-68 DOTATATE, Ga-68 PSMA, F-18 fluciclovine, etc.) are used in these contexts.
• Small lesion limit. Even modern digital scanners are challenged by sub-4-mm lesions; the partial-volume effect causes substantial underestimation of true SUV in small lesions. This is an inherent physical limit of PET imaging.
• Quantitative reproducibility depends on scanner standardisation. Cross-centre quantitative comparison requires participation in standardisation programmes (EARL, SNMMI Clinical Trials Network). Without standardisation, SUV values from different scanners are not directly comparable.
• Interpretation requires expertise. A normal report from a low-volume centre using an old scanner is not equivalent to a normal report from a high-volume centre using a modern digital scanner with expert nuclear medicine interpretation. The infrastructure matters.

Regulatory framework and quality standards

PET-CT scanning operates under multi-layered regulatory and quality-standards frameworks^[16]:

• AERB (Atomic Energy Regulatory Board, India) — Safety Code AERB/RF-MED/SC-2 (Rev. 2) governs the medical use of radioactive substances in India, including PET radiopharmaceuticals.
• DCGI / CDSCO — regulates the radiopharmaceuticals themselves under the Drugs and Cosmetics Act.
• EANM (European) procedure guidelines — primary international reference for FDG PET-CT and receptor-targeted PET protocols; widely adopted in Indian and other international centres.
• SNMMI (US) practice standards — additional international reference for PET-CT procedure standards.
• EARL accreditation — voluntary quantitative-standardisation accreditation programme for PET-CT scanners; participating centres can produce SUV measurements that are comparable across institutions.
• NABH (Indian) and JCI (international) hospital accreditation — institutional quality standards.

For an oncology referrer or international patient, the practical assurance from this framework is that a PET-CT scan performed at an AERB-licensed, NABH-accredited centre using a modern digital scanner under EANM-aligned protocols meets internationally-recognised quality standards.

The bottom line

• Modern PET-CT uses silicon photomultiplier (SiPM) digital detectors that provide 2-3× sensitivity improvement, 2-4 mm spatial resolution, and 30-50% radiation dose reduction compared with analog photomultiplier-tube scanners^[1].
• Digital PET-CT scanner platforms (Siemens Biograph Vision, GE Discovery MI, Philips Vereos, United Imaging uMI Vista) are now in widespread clinical use; underlying technology improvements are broadly similar across vendors^[6].
• AI-based image reconstruction (Bayesian penalised-likelihood, deep-learning denoising) further improves image quality and supports dose reduction or shorter scan time^[8].
• Clinical advantages: smaller lesion detection (4-6 mm reliably characterised), shorter scan time (5-10 min on digital vs 15-20 min on legacy), lower injected dose, more accurate SUV quantification^[7].
• Particular benefit for receptor-targeted PET (Ga-68 PSMA, Ga-68 DOTATATE) — better detection of small nodal and skeletal metastases at low PSA / low disease burden^[11].
• Typical total radiation dose ~5-12 mSv for FDG PET-CT (modern digital), within range of standard cancer imaging and justified by diagnostic value^[13].
• Quality standards include EANM procedure guidelines, EARL quantitative-standardisation accreditation, AERB Safety Code SC-2, and NABH / JCI hospital accreditation^[16].